Asset Details
Do you wish to reserve the book?
Adult height and health-related quality of life in patients born small for gestational age treated with recombinant growth hormone
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adult height and health-related quality of life in patients born small for gestational age treated with recombinant growth hormone
Do you wish to request the book?
Adult height and health-related quality of life in patients born small for gestational age treated with recombinant growth hormone
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adult height and health-related quality of life in patients born small for gestational age treated with recombinant growth hormone
2023
Overview
Health related quality of life (HRQoL) is a relevant result when assessing the course of different pathologies and the efficacy of their treatments. HRQoL has been studied previously on adults born small for gestational age (SGA), both in the general population and in patients who had received recombinant human growth hormone (rhGH) treatment, with disparate results. Our study included 50 adults who had received rhGH treatment for the SGA indication in 4 Spanish hospitals. Data have been gathered retrospectively from their clinical records, current weight and height were measured, and patients have been asked to fill out SF-36 and QoLAGHDA quality of life forms, and the Graffar test to evaluate their socio-economical status. Patient’s adult height was – 1.2 ± 0.9 SD, lower than their target height of 1 ± 0.8 SD, but gaining 1.7 ± 1 SD from the beginning of the treatment. SF-36 test results showed lower scoring on Mental Health domains than on those related to Physical Health. No correlation was found between HRQoL results and final height, rhGH treatment duration or puberty. Correlation was indeed found between QoLAGHDA and several domains of SF-36, but QoLAGHDA detected fewer patients with low HRQoL than SF-36. Thus, it is concluded that SGA patient’s follow-up should include a HRQoL, neuro-cognitive and psychiatric assessment in their transition to adult age. Adult SGA patients without catch up growth have impaired HRQoL, especially in mental health domains.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/308
/ 692/700
/ Adult
/ Adults
/ Age
/ Growth Disorders - drug therapy
/ Growth Disorders - psychology
/ Human Growth Hormone - therapeutic use
/ Humanities and Social Sciences
/ Humans
/ Infant, Small for Gestational Age - growth & development
/ Infant, Small for Gestational Age - psychology
/ Patients
/ Puberty
/ Recombinant Proteins - therapeutic use
/ Science
